AIM ImmunoTech announced positive interim results from its Phase 2 DURIPANC study combining Ampligen (rintatolimod) with AstraZeneca's Imfinzi (durvalumab) for treating metastatic pancreatic cancer. The trial has completed patient enrollment and is on track for a primary endpoint evaluation in December 2026, focusing on clinical benefit rate at 6 months. Previous data showed Ampligen monotherapy extended median survival significantly, and the company plans a pivotal Phase 3 trial to further assess survival and safety. This progress highlights potential new treatment options for a cancer with limited effective therapies.
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
